Outlook Therapeutics, Inc.
Healthcare · EUR · F
41O
Price
€0.28
+25.66%
Cap
€34.33M
Earnings
—
30d Trend
+20.3%
41O
Loading chart data...
0 days · % change from startPowered by Brain47
52-week range5%
€0.15€2.78
Near 52-week lows — potential value or falling knife
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulatio…
BRAIN47 SIGNAL
Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.
Running historical backtest...
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.